Immunohistochemical expression of HER2 in breast cancer: socioeconomic impact of inaccurate tests

被引:0
作者
Mogens Vyberg
Søren Nielsen
Rasmus Røge
Beth Sheppard
Jim Ranger-Moore
Eric Walk
Juliane Gartemann
Ulrich-Peter Rohr
Volker Teichgräber
机构
[1] NordiQC,
[2] Institute of Pathology,undefined
[3] Aalborg University Hospital,undefined
[4] Ventana Medical Systems Inc,undefined
[5] F. Hoffmann-La Roche Ltd,undefined
[6] Diagnostics Division,undefined
[7] Divisional Medical and Scientific Affairs,undefined
来源
BMC Health Services Research | / 15卷
关键词
Trastuzumab; Additional Life Expectancy;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
相关论文
共 30 条
[1]  
Jemal A(2011)Global cancer statistics CA Cancer J Clin 61 69-90
[2]  
Bray F(2009)The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine Oncologist 14 320-368
[3]  
Center MM(2007)Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients Breast Cancer Res 9 R6-1434
[4]  
Ferlay J(2011)Results of a Belgian multicentre retrospective study to determine the incidence of HER2 gene amplification in patients scored as immunohistochemistry 0 or 1+ J Clin Oncol 29 abstr 549-543
[5]  
Ward E(2007)Testing for HER2-positive breast cancer: a systematic review and cost-effectiveness analysis CMAJ 176 1429-undefined
[6]  
Forman D(2008)Proficiency testing of immunohistochemical biomarker assays in breast cancer Virchows Arch 453 537-undefined
[7]  
Ross JS(undefined)undefined undefined undefined undefined-undefined
[8]  
Slodkowska EA(undefined)undefined undefined undefined undefined-undefined
[9]  
Symmans WF(undefined)undefined undefined undefined undefined-undefined
[10]  
Pusztai L(undefined)undefined undefined undefined undefined-undefined